A citation-based method for searching scientific literature

Nitesh D Kuhadiya, Ben Prohaska, Husam Ghanim, Paresh Dandona. Diabetes Obes Metab 2019
Times Cited: 2







List of co-cited articles
11 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein,[...]. Lancet Diabetes Endocrinol 2017
134
100

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
87
100


SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.
Simeon I Taylor, Jenny E Blau, Kristina I Rother, Amber L Beitelshees. Lancet Diabetes Endocrinol 2019
22
100

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
106
100

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
190
100

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode,[...]. Diabetes Care 2019
96
100

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
95
100

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya,[...]. Diabetes Care 2018
110
100

Adjunct therapies in treatment of type 1 diabetes.
Itivrita Goyal, Alamgir Sattar, Megan Johnson, Paresh Dandona. J Diabetes 2020
3
100

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
597
100

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
71
50


Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study.
Kamlesh Khunti, Melanie Davies, Azeem Majeed, Brian Larsen Thorsted, Michael Lyng Wolden, Sanjoy K Paul. Diabetes Care 2015
173
50

Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial.
Thomas F Dejgaard, Signe Schmidt, Christian S Frandsen, Dorte Vistisen, Sten Madsbad, Henrik U Andersen, Kirsten Nørgaard. Diabetes Obes Metab 2020
5
50

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Kevan C Herold, Stephen E Gitelman, Mario R Ehlers, Peter A Gottlieb, Carla J Greenbaum, William Hagopian, Karen D Boyle, Lynette Keyes-Elstein, Sudeepta Aggarwal, Deborah Phippard,[...]. Diabetes 2013
183
50

High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database.
Sabita S Soedamah-Muthu, John H Fuller, Henrietta E Mulnier, Veena S Raleigh, Ross A Lawrenson, Helen M Colhoun. Diabetes Care 2006
235
50



Autoreactive T cells in type 1 diabetes.
Alberto Pugliese. J Clin Invest 2017
118
50

Autoimmune aspects of type 2 diabetes mellitus - a mini-review.
Bianca K Itariu, Thomas M Stulnig. Gerontology 2014
52
50

Targeting Interleukin-6 Signaling in Clinic.
Sujin Kang, Toshio Tanaka, Masashi Narazaki, Tadamitsu Kishimoto. Immunity 2019
205
50

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
697
50

How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited.
Mark A Atkinson, Jeffrey A Bluestone, George S Eisenbarth, Matthias Hebrok, Kevan C Herold, Domenico Accili, Massimo Pietropaolo, Peter R Arvan, Matthias Von Herrath, Dorene S Markel,[...]. Diabetes 2011
135
50

Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial.
Ryotaro Bouchi, Yujiro Nakano, Tatsuya Fukuda, Takato Takeuchi, Masanori Murakami, Isao Minami, Hajime Izumiyama, Koshi Hashimoto, Takanobu Yoshimoto, Yoshihiro Ogawa. Endocr J 2017
42
50


SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
198
50

Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
John A Todd, Marina Evangelou, Antony J Cutler, Marcin L Pekalski, Neil M Walker, Helen E Stevens, Linsey Porter, Deborah J Smyth, Daniel B Rainbow, Ricardo C Ferreira,[...]. PLoS Med 2016
61
50

Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function.
Jordan Rowlands, Julian Heng, Philip Newsholme, Rodrigo Carlessi. Front Endocrinol (Lausanne) 2018
61
50

The challenge of modulating β-cell autoimmunity in type 1 diabetes.
Mark A Atkinson, Bart O Roep, Amanda Posgai, Daniel C S Wheeler, Mark Peakman. Lancet Diabetes Endocrinol 2019
49
50

Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
Ronnie Aronson, Peter A Gottlieb, Jens S Christiansen, Thomas W Donner, Emanuele Bosi, Bruce W Bode, Paolo Pozzilli. Diabetes Care 2014
67
50

The healthy exocrine pancreas contains preproinsulin-specific CD8 T cells that attack islets in type 1 diabetes.
Christine Bender, Teresa Rodriguez-Calvo, Natalie Amirian, Ken T Coppieters, Matthias G von Herrath. Sci Adv 2020
14
50

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Fred Whitehouse, Davida F Kruger, Mark Fineman, Larry Shen, James A Ruggles, David G Maggs, Christian Weyer, Orville G Kolterman. Diabetes Care 2002
185
50

Concordance for islet autoimmunity among monozygotic twins.
Maria J Redondo, Joy Jeffrey, Pamela R Fain, George S Eisenbarth, Tihamer Orban. N Engl J Med 2008
146
50


Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
Kristina I Rother, Lisa M Spain, Robert A Wesley, Benigno J Digon, Alain Baron, Kim Chen, Patric Nelson, H-Michael Dosch, Jerry P Palmer, Barbara Brooks-Worrell,[...]. Diabetes Care 2009
95
50

Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol.
Anette-Gabriele Ziegler, Peter Achenbach, Reinhard Berner, Kristina Casteels, Thomas Danne, Melanie Gündert, Joerg Hasford, Verena Sophia Hoffmann, Olga Kordonouri, Karin Lange,[...]. BMJ Open 2019
19
50

Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes.
Jenny Aurielle B Babon, Megan E DeNicola, David M Blodgett, Inne Crèvecoeur, Thomas S Buttrick, René Maehr, Rita Bottino, Ali Naji, John Kaddis, Wassim Elyaman,[...]. Nat Med 2016
156
50

Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.
William Hagopian, Robert J Ferry, Nicole Sherry, David Carlin, Ezio Bonvini, Syd Johnson, Kathryn E Stein, Scott Koenig, Anastasia G Daifotis, Kevan C Herold,[...]. Diabetes 2013
115
50

An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice.
Liliane Khoryati, Minh Nguyet Pham, McKenna Sherve, Swarnima Kumari, Kevin Cook, Josh Pearson, Marika Bogdani, Daniel J Campbell, Marc A Gavin. Sci Immunol 2020
7
50

Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
Araz Rawshani, Naveed Sattar, Stefan Franzén, Aidin Rawshani, Andrew T Hattersley, Ann-Marie Svensson, Björn Eliasson, Soffia Gudbjörnsdottir. Lancet 2018
189
50

SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution.
Joseph I Wolfsdorf, Robert E Ratner. Diabetes Care 2019
11
50

Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.
Jeffrey P Krischer, Desmond A Schatz, Brian Bundy, Jay S Skyler, Carla J Greenbaum. JAMA 2017
65
50

Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine.
Bart O Roep, Daniel C S Wheeler, Mark Peakman. Lancet Diabetes Endocrinol 2019
45
50


Current progress in stem cell therapy for type 1 diabetes mellitus.
Shuai Chen, Kechen Du, Chunlin Zou. Stem Cell Res Ther 2020
7
50

Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort.
Rachel G Miller, Aaron M Secrest, Ravi K Sharma, Thomas J Songer, Trevor J Orchard. Diabetes 2012
143
50

Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.
Christopher C Patterson, Suvi Karuranga, Paraskevi Salpea, Pouya Saeedi, Gisela Dahlquist, Gyula Soltesz, Graham D Ogle. Diabetes Res Clin Pract 2019
68
50

Human herpesvirus-6 is present at higher levels in the pancreatic tissues of donors with type 1 diabetes.
Somayeh Sabouri, Mehdi A Benkahla, William B Kiosses, Teresa Rodriguez-Calvo, Jose Zapardiel-Gonzalo, Ericka Castillo, Matthias G von Herrath. J Autoimmun 2020
4
50

Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?).
Bart O Roep, Sofia Thomaidou, René van Tienhoven, Arnaud Zaldumbide. Nat Rev Endocrinol 2021
22
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.